Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 4 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 8 months ago

Prevention & Chronic Conditions
Diversity in Cardiovascular Disease: Are we Failing the General Population?
Author(s): Martha Gulati Added: 1 year ago
In this video series recorded at ACC 2024 in Atlanta, US, Prof Martha Gulati (Cedars-Sinai Smidt Heart Institute, Los Angeles, US) unveils pivotal data from four posters addressing the pressing issue of inequality in cardiology and healthcare. Gain a deeper understanding of personalised treatment approaches, recognise the importance of inclusivity in clinical trials and confront disparities in… View more

CV Disease in Special Populations
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
HsCRP in ASCVD
Author(s): Adhya Mehta , Roger S Blumenthal , Ty J Gluckman , et al Added: 10 months ago

Prevention & Chronic Conditions
Bariatric Surgery: Reduced CVD Risk via PREVENT Equations
Author(s): Danxia Yu Added: 9 months ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 2 years ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
AHA 24: The LIBerate-OLE Trial
Author(s): Dean J Kereiakes Added: 1 year ago
AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE … View more

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Chest Pain in Women
Author(s): Mariem A Sawan , Rebecca S Steinberg , Michael N Sayegh , et al Added: 2 years ago

Demographic

Prevention & Chronic Conditions